Chris Wilson is a partner in the Antitrust Department. Wilson advises clients on a full range of antitrust matters, including merger control, cross-border antitrust investigations and private party litigation involving complex antitrust and consumer protection issues, including matters implicating the Hart-Scott-Rodino (HSR) merger review process, the Sherman Act, the Clayton Act, the FTC Act, and international and state competition statutes.
Wilson’s areas of expertise include merger enforcement, interlocking directorates, joint ventures, compliance programs, and employee “no-poach” agreements. He has advised on cross-border investigations involving the European Union, the United Kingdom, Canada, Brazil, Japan, Korea and Saudi Arabia, among other jurisdictions, and has handled merger reviews and other antitrust matters involving multiple industries, including health insurance, transportation, telecommunications, technology, energy, agriculture and biotechnology.
Lawdragon Honors
| Honor | Year | Practice |
|---|---|---|
| The 2027 Lawdragon 500 Leading Litigators in America | 2027 | Antitrust, Investigations, Litigation |
| The 2026 Lawdragon 500 Leading Global Antitrust & Competition Lawyers | 2026 | Antitrust, M&A, Clearance, Litigation |
| The 2026 Lawdragon 500 Leading Litigators in America | 2026 | Antitrust, Investigations, Litigation |
| The 2025 Lawdragon 500 Leading Global Antitrust & Competition Lawyers | 2025 | Antitrust, M&A, Clearance, Litigation |
Prior to his private practice, Wilson was a trial attorney in the Transportation, Energy & Agriculture Section of the U.S. Department of Justice’s Antitrust Division. During his time in the Division, he managed or played a key role in numerous high-profile matters, including merger reviews for Halliburton-Baker Hughes, Aetna-Humana, Anthem-Cigna, Alaska Airlines-Virgin and CVS-Aetna. Chris received the Antitrust Division’s Award of Distinction on two separate occasions.
Wilson’s notable representations include:
- Chevron in its $55 billion acquisition of Hess;
- Rocket Companies in its $1.75 billion acquisition of Redfin;
- Endeavor Energy Resources in its $26 billion merger with Diamondback Energy;
- Envestnet in its $4.5 billion take-private deal with Bain Capital;
- Pioneer Natural Resources in its $65 billion merger with ExxonMobil;
- Platinum Equity in its $5.25 billion acquisition of Solenis;
- GE Healthcare in its $1.45 billion acquisition of BK Medical;
- Xylem in its $7.5 billion acquisition of Evoqua;
- Spark Therapeutics in its $4.3 billion sale to Roche; and
- Stone Canyon Industries in its $3 billion acquisition of Morton Salt.